Floatz logo

IMMUNOGLOBULIN G2-KAPPA, ANTI-(HOMO SAPIENS DLL4(DELTA-LIKE 4)) AND ANTI-(HOMO SAPIENS VEGFA (VASCULAR ENDOTHELIAL GROWTH FACTOR A,VEGF-A, VEGF)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC

Advanced Solid Tumor Malignancies

OncoMed Pharmaceuticals, Inc.monoclonal_antibodyPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

928 Active assets in the Advanced Solid Tumor Malignancies cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
Inno-206
The First Affiliated Hospital of Soochow University
Phase 2/3BB
DINITROGEN MONOXIDE
Medical College of Wisconsin
Phase 4BB
Glycopyrrolate
Medical College of Wisconsin
Phase 4BB

View all 50 →

Same molecule, other indications

IMMUNOGLOBULIN G2-KAPPA, ANTI-(HOMO SAPIENS DLL4(DELTA-LIKE 4)) AND ANTI-(HOMO SAPIENS VEGFA (VASCULAR ENDOTHELIAL GROWTH FACTOR A,VEGF-A, VEGF)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC is also rated in:

ovarian cancerDormant
CC
Indicative ·
47 / 100
View asset →
peritoneum cancerDormant
CC
Indicative ·
47 / 100
View asset →
fallopian tube cancerDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →